News

OneSource Specialty Pharma Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for dealing in shares of the company will be closed from Thursday, October 01, 2026, until 48 hours after the declaration of financial results for the quarter ended September 30, 2026.

OneSource Specialty Pharma Limited announced that shareholders appointed M/s B S R & Co LLP, Chartered Accountants (Firm’s Registration No.:101248W/W-100022), as its statutory auditors for a period of 5 consecutive years, effective from the conclusion of the 19th Annual General meeting until the conclusion of the 24th Annual General Meeting, during a meeting held on Wednesday, September 23, 2026.

Net profit of OneSource Specialty Pharma reported to Rs 25.00 crore in the quarter ended June 2026 as against net loss of Rs 0.19 crore during the previous quarter ended June 2025. Sales rose 37.20% to Rs 449.02 crore in the quarter ended June 2026 as against Rs 327.27 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales449.02327.27 37 OPM %27.4727.04 - PBDT96.3466.27 45 PBT24.59-1.53 LP NP25.00-0.19 LP Powered by Capital Market - Live News

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 24 July 2026.

OneSource Specialty Pharma and Formycon AG, an independent biosimilar developer headquartered in Munich, today announced a strategic manufacturing partnership for biosimilars. Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics` facility in Bangalore. The collaboration brings together Formycon�s Biosimilar development excellence with OneSource`s end-to-end biologics manufacturing expertise to support Formycon`s biosimilar programs for global markets.